AGAP7P

Across TCGA pan-cancer cohorts, AGAP7P Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AGAP7P data layer compared with 21 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher AGAP7P Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AGAP7P expression acts as an unfavorable survival marker.

SCLC, BLCA, and SKCM are the cancer types where AGAP7P Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.137	0.700	<.001	48	view →
BLCA	OS	Median	All	0.183	0.720	.001	18	view →
SKCM	OS	Median	All	0.123	0.346	.001	14	view →
LIHC	DFS	Median	All	0.041	0.556	<.001	9	view →
LGG	DFS	Median	All	0.156	0.753	<.001	6	view →
LUAD	OS	Median	All	0.333	0.700	.031	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AGAP7P–SCLC (OS)

Open the SCLC breakdown →